Ann: XanaHES Trial to Continue, page-26

There is no relationship between carbenoxolone other than the fact that they both have the ability to inhibit 11 bhsd and can both penetrate the blood brain barrier. Xanamem is a selective inhibitor, meaning it inhibits type 1 of 11b hsd rather than the non selective carbenoxolone which inhibits both isozymes. Basically, the cognitive enhancing results seen in the carbenoxolone study should be replicated by xanamem due to the fact it is designed and tested to be a better inhibitor with minimal side effects.

As for the announcement yesterday. It wasn't groundbreaking news but I suppose it is one less thing to worry about. Safety at these levels have been tested in the past over shorter periods. Safety has never been a concern with xanamem for me. Bill said that extremely high doses have been known to be toxic. But you could say that about water also. The wording of the opening statement was the most intriguing thing to me. The announcement opened similar to every bad announcement I have ever read.

But anyway, all we can do is wait for XanADu results and hopefully the path forward is favourable to SHs and sufferers of cognitive impairment. Best case the expanded data set lands us a partnership.